VSTM Verastem Inc.

3.70
+0.08  (2%)
Previous Close 3.62
Open 3.68
Price To book 3.66
Market Cap 149810765
Shares 40,489,396
Volume 293,721
Short Ratio 2.14
Av. Daily Volume 736,730

SEC filingsSee all SEC filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 171181137
  2. 8-K - Current report 171139839
  3. 8-K/A [Amend] - Current report 171099916
  4. 8-K - Current report 171091059
  5. 8-K - Current report 171070166

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial to be initiated by the end of 2017.
Duvelisib
Peripheral T-Cell Lymphoma (PTCL)
Phase 1/2 initiation of dosing announced January 26, 2017.
Avelumab and defactinib
Ovarian cancer
Phase 1/2 initial data - 21st Congress of European Hematology Association June 9 - 12, 2016
Duvelisib - Conetempo
Treatment-naïve patients with follicular lymphoma
Phase 2 data released June 2016 - short of expectations
Duvelisib (IPI-145) DYNAMO
Indolent non-Hodgkin lymphoma
Phase 3 data released September 6, 2017 - primary endpoint met with NDA filing due 1Q 2018.
Duvelisib - DUO
Cancer - relapsed/refractory chronic lymphocytic leukemia (CLL)
Phase 2 interim analysis showed lack of efficacy. Trial stopped. September 2015
VS-6063
Mesothelioma prior to surgery
Phase 2 failed to meet endpoint - Jan 2015
Duvelisib (IPI-145)
Rheumatoid arthritis

Latest News

  1. Options Traders Expect Huge Moves in Verastem (VSTM) Stock
  2. Research Report Identifies Hill-Rom, TASER International, Synchronoss Technologies, NuVasive, Verastem, and Roku with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
  3. Verastem to Present at Upcoming Investor Conferences
  4. Verastem reports 3Q loss
  5. Verastem Reports Third Quarter 2017 Financial Results
  6. Corporate News Blog - Verastem Announces Plans to Submit NDA Requesting Full Approval of Duvelisib for Treatment of Patients with Relapsed or Refractory CLL/SLL
  7. Verastem Announces Data from Phase 3 DUO Study Selected for Oral Presentation at the American Society of Hematology 2017 Annual Meeting
  8. Verastem Announces Regulatory Strategy for Duvelisib New Drug Application Following Guidance from FDA
  9. Verastem Pays Milestone Payment to Infinity Pharmaceuticals
  10. Verastem Appoints NgocDiep Le, MD, PhD as Chief Medical Officer
  11. Verastem to Present at the Cantor Fitzgerald Global Healthcare Conference
  12. Today's Research Reports on Stocks to Watch: Moleculin Biotech and Verastem
  13. Verastem Shares Are Exploding 50% -- Here's Why
  14. Verastem's blood cancer drug succeeds in late-stage trial
  15. Verastem Expands Duvelisib Development Program to Include Peripheral T-Cell Lymphoma
  16. Verastem Announces Positive Top-line Data from the Pivotal Phase 3 DUO™ Study in Relapsed or Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
  17. Implied Volatility Surging for Verastem (VSTM) Stock Options
  18. Verastem Reports Second Quarter 2017 Financial Results
  19. Verastem Publishes Scientific Data Highlighting Potential Role of FAK Inhibition in Pancreatic and Breast Cancer
  20. Today's Research Reports on Stocks to Watch: Alder BioPharmaceuticals Inc. and Verastem Inc.

SEC Filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 171181137
  2. 8-K - Current report 171139839
  3. 8-K/A [Amend] - Current report 171099916
  4. 8-K - Current report 171091059
  5. 8-K - Current report 171070166
  6. 8-K - Current report 171055039
  7. 424B5 - Prospectus [Rule 424(b)(5)] 171054998
  8. 10-Q - Quarterly report [Sections 13 or 15(d)] 171014944
  9. SC 13G - Statement of acquisition of beneficial ownership by individuals 17974726
  10. 8-K - Current report 17960101